ArticleFrontiers in immunology2025

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China.

Zhengxiong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.